Key statistics
As of last trade Regenxbio Inc (RB0:FRA) traded at 8.75, 4.17% above its 52-week low of 8.40, set on Oct 04, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 8.75 |
---|---|
High | 8.75 |
Low | 8.75 |
Bid | 8.55 |
Offer | 8.65 |
Previous close | 8.40 |
Average volume | 498.63 |
---|---|
Shares outstanding | 49.42m |
Free float | 45.76m |
P/E (TTM) | -- |
Market cap | 480.39m USD |
EPS (TTM) | -5.27 USD |
Data delayed at least 15 minutes, as of Oct 07 2024 07:06 BST.
More ▼
Press releases
- REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines Conference
- REGENXBIO Appoints Mitchell Chan as Chief Financial Officer
- REGENXBIO Announces Positive Data from Pivotal Dose Level of RGX-121 Demonstrating Long-Term Systemic Effect
- REGENXBIO to Participate in Upcoming Investor Conferences
- REGENXBIO Announces Presentation at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium
- REGENXBIO to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
- REGENXBIO Reports Second Quarter 2024 Financial Results and Recent Operational Highlights
- REGENXBIO ANNOUNCES NEW POSITIVE DATA FROM AFFINITY DUCHENNE® TRIAL OF RGX-202
- REGENXBIO to Host Conference Call on August 1 to Discuss Second Quarter 2024 Financial Results and Recent Operational Highlights
- REGENXBIO Announces Pivotal Trial of RGX-121 for the Treatment of MPS II Achieves Primary Endpoint
More ▼